KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

PURPOSE: VEGF pathway inhibitors have been investigated as therapeutic agents in the treatment of non–small cell lung cancer (NSCLC) because of its central role in angiogenesis. These agents have improved survival in patients with advanced NSCLC, but the effects have been modest. Although VEGFR2/KDR...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Nilsson, Monique B., Giri, Uma, Gudikote, Jayanthi, Tang, Ximing, Lu, Wei, Tran, Hai, Fan, Youhong, Koo, Andrew, Diao, Lixia, Tong, Pan, Wang, Jing, Herbst, Roy, Johnson, Bruce E., Ryan, Andy, Webster, Alan, Rowe, Philip, Wistuba, Ignacio I., Heymach, John V.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4834253/
https://ncbi.nlm.nih.gov/pubmed/26578684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1994
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados